Bill Keating Email and Phone Number

Delivering Interpretable AI/ML-powered insights, validated by Real-World Data, from Target Discovery to Label Optimization

Foundation Medicine, Inc. (FMI) simplified the complex nature of cancer genomics, by delivering industry-leading and FDA-cleared technology to everyday cancer care. FMI generates insights that help doctors match patients to more treatment options and accelerates the development of new cancer therapies.Led a business development/alliance management team which secured new business opportunities with new biopharmaceutical clients, including new Companion Diagnostics (CDx) strategic partnerships. Negotiated to closure new Master Services Agreements (MSAs) for genomic profiling, delivery of genomic data insights, as well as multi-year CDx engagements.

Enabled accelerated drug development and translational studies, by delivering Digital and Computational Pathology solutions (equipment, software and services) which delivered superior precision medicine diagnostics.Drove the evaluation and adoption of Philips' Digital and Computational Pathology diagnostic solutions, specifically targeted to biopharma clients and CROs, and relative adjacencies.

Cell Signaling Technology (CST) is a private, life science tools developer, active in the field of applied systems biology research, particularly as it relates to cancer, neurobiology and other impactful diseases.Implemented market-enabling strategies, allowing CST to penetrate the adjacent in vitro diagnostics (IVD) market, by establishing strategic partnerships with select diagnostic platform manufacturers, particularly in Immuno-histochemistry (IHC), Multiplex spatial profiling, flow cytometry and other platforms. Particular focus on oncology, and emerging modality of Immuno-oncology.

Led the establishment of Digital PCR in Molecular Diagnostics, by offering transformative technologies for targeted DNA sequencing and digital PCR, for the research and earlier diagnosis of cancer.Led all aspects of business development; technology licensing, strategic partnerships, sponsored research collaborations, competitive monitoring and strategic positioning.Closed the transformative deal with the market-leading clinical sequencing laboratory., including equity investment.

Experienced in all aspects of business development, including valuations, divestitures, technology in/out-licensing, research collaborations and strategic partnerships.

Lead breakthrough assignment team in new technology development for critical care diagnostic test development.Oversaw strategic marketing, and convened world-renowned expert advisory board, performed competitive intelligence and voice-of-customer collection.Work has resulted in the filing of 22 WW patent applications, 5 issued patents, 14 scientific presentations, and 5 journal publications (published or in press).

Directed several Molecular Diagnostics Product Development teams to successful WW launch of several molecular diagnostic product lines, including CE-Marking, FDA clearance and Japanese MHW approval.

Optimized proprietary DNA amplification technology, Strand Displacement Amplification (SDA), which became the core technology underpinning BD's current Molecular Diagnostics business.Inventor of several specimen processing techniques for molecular diagnostics.

Performed radioimmunoassays (RIA) and esoteric testing on submitted patient specimens.